References
- Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl Cancer Inst.85(9), 704–701 (1993).
- DeAngelis LM. Brain tumors. N. Engl. J. Med.344(2), 114–123 (2001).
- Garside R, Pitt M, Anderson R et al. The effectiveness and cost–effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol. Assess. 2007.11, 45 (2007).
- Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med.359, 492–507 (2008).
- Glioma Meta-Analysis Group. Chemotherapy in adult high-grade glioma: a systematic reviw and meta-analysis of individual patient data from 12 randomised trials. Lancet359, 1011–1018 (2002).
- Stupp R, Dietrich PY, Ostermann Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol.20(5), 1375–1382 (2002).
- Lanzetta G, Campanella C, Rozzi A et al. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: Phase II clinical trial. Anticancer Res.23(6D), 5159–5164 (2003).
- Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
- Athanassiou H, Synodinou M, Maragoudakis E et al. Randomized Phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J. Clin. Oncol.23(10), 2372–2377 (2005).
- Stupp R, Hegi ME, Mason WP et al. Is long-term survival possible in gliobastoma? Final report of the EORTC-NCIC randomized Phase III trial of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone. Lancet Oncol. (2009) (In Press).
- Wasserfallen JB, Ostermann S, Leyvraz S, Stupp R. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol.7(2), 189–195 (2005).
- Lamers LM, Stupp R, van den Bent MJ et al. Cost–effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer12(6), 1337–1344 (2008).
- Taphoorn MJ, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol.6(12), 937–944 (2005).
- Yung WKA, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer83, 588–593 (2000).
- Brada M, Hoang-Xuan K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol.12, 259–266 (2000).
- Uyl-de Groot CA, Giaccone G. Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Curr. Opin. Oncol.17, 392–396 (2005).